الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 143 |  |  |
| | | from | 143 | | |
Abstract
Coronary artery disease (CAD)remains the most serious threat to life and health in industrialized countries. The main triggering event of unstable coronary heart disease is rupture of an atherosclerotic plaque with superimposed thrombosis . The fibrinolytic pathway is important in the maintenance of blood flow ,ensuring that fibrin clot formation is localized to the site of vascular injury and the clot is dissolved . many of the proteins involved in fibrinolysis that might contribute to a thrombotic tendency are in fact related to the development of coronary artery disease. The suppression of fibrinolysis due to high plasma concentrations of plasminogen- activator inhibitor type 1 (PAI-1) and fibrinogen are associated with the development of acute coronary syndrome. In addition, high concentrations of tissue plasminogen activator (t-PA) and D-dimer increase the risk of coronary artery disease . High plasma levels of Thrombin activable fibrinolysis inhibitor (TAFI)were recognized in patients with symptomatic coronary disease and patients with acute ischemic . The laboratory is involved in research and development of diagnostic tests and their clinical application and in providing cost-effective assays that enhance and expedite the diagnostic process.
Thrombolytic therapy is the use of drugs to break up or dissolve blood clots, which are the main cause of both myocardial infarction (MI) and stroke.. The most commonly used and most effective drug for thrombolytic therapy is tissue plasminogen activator (tPA) , but other drugs can be used for the same purpose, including reteplase , urokinase , andstreptokinase.